Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$1.68 - $2.52 $166,320 - $249,480
99,000 Added 135.62%
172,000 $288,000
Q1 2024

May 07, 2024

BUY
$1.75 - $2.95 $84,175 - $141,895
48,100 Added 193.17%
73,000 $188,000
Q4 2023

Feb 14, 2024

BUY
$0.53 - $2.0 $13,197 - $49,800
24,900 New
24,900 $49,000
Q3 2022

Nov 14, 2022

BUY
$0.66 - $2.32 $62,436 - $219,471
94,600 Added 345.26%
122,000 $81,000
Q2 2022

Aug 15, 2022

SELL
$1.57 - $3.33 $54,322 - $115,218
-34,600 Reduced 55.81%
27,400 $51,000
Q1 2022

May 16, 2022

BUY
$2.76 - $4.64 $89,976 - $151,264
32,600 Added 110.88%
62,000 $200,000
Q4 2021

Feb 14, 2022

SELL
$4.09 - $7.16 $497,344 - $870,656
-121,600 Reduced 80.53%
29,400 $126,000
Q3 2021

Nov 15, 2021

BUY
$5.8 - $8.02 $614,220 - $849,318
105,900 Added 234.81%
151,000 $901,000
Q2 2021

Aug 11, 2021

SELL
$6.87 - $9.16 $278,235 - $370,980
-40,500 Reduced 47.31%
45,100 $373,000
Q1 2021

May 17, 2021

SELL
$7.67 - $13.77 $628,173 - $1.13 Million
-81,900 Reduced 48.9%
85,600 $735,000
Q3 2020

Nov 16, 2020

BUY
$14.16 - $19.45 $1.79 Million - $2.45 Million
126,200 Added 305.57%
167,500 $2.72 Million
Q2 2020

Aug 14, 2020

SELL
$6.97 - $17.12 $124,066 - $304,736
-17,800 Reduced 30.12%
41,300 $620,000
Q1 2020

May 15, 2020

BUY
$5.79 - $11.83 $210,177 - $429,429
36,300 Added 159.21%
59,100 $429,000
Q3 2019

Nov 14, 2019

BUY
$3.01 - $4.49 $9,632 - $14,368
3,200 Added 16.33%
22,800 $96,000
Q2 2019

Aug 14, 2019

SELL
$2.8 - $4.14 $40,880 - $60,443
-14,600 Reduced 42.69%
19,600 $75,000
Q1 2019

May 15, 2019

BUY
$2.35 - $4.19 $43,475 - $77,515
18,500 Added 117.83%
34,200 $142,000
Q1 2018

May 15, 2018

BUY
$2.5 - $4.45 $39,250 - $69,865
15,700 New
15,700 $70,000

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $142M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.